Sunscreen TEAs
This article was originally published in The Tan Sheet
Executive Summary
FDA requests safety and efficacy data on three sunscreens based on its determination that time and extent applications indicate the ingredients are "eligible for consideration" for inclusion in OTC monograph, according to 1July 11 Federal Register notice. Data sought on amiloxate (isoamyl p-methoxycinnamate), enzacamene (methyl benzylidene camphor) and octyl triazone by Oct. 9. TEAs for ingredients were filed by Haarmann & Reimer, Merck KgaA and BASF AG, respectively. Agency will make a final decision on ingredients' status following review of submitted information...
You may also be interested in...
Octyl triazone
BASF asks for 90-day extension to respond to FDA's request for data on octyl triazone sunscreen; the previous deadline was Oct. 9. Firm maintains more time is needed to compile recent effectiveness data. Beiersdorf submitted a separate letter Oct. 7 in support of BASF's time and extent application, noting the German firm has used the ingredient in its own sun care products outside the U.S. for more than five years without "unusual adverse event experience." FDA requested safety data on octyl triazone and two other sunscreen ingredients in a July 11 Federal Register notice (1"The Tan Sheet" July 14, 2003, In Brief)...
Octyl Triazone Sales Of 400 Mil. Sunscreen Units Abroad Cited By FDA
Based on bulk material sales, nearly 400 mil. sunscreen dosage units containing octyl triazone have been sold in 35 countries, FDA notes in an evaluation of BASF's time and extent application for including the ingredient in the OTC sunscreen monograph
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.